courpharmapeanuttrial.com

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Allow: / # Optimization for Google Ads Bot User-agent: AdsBot-Google-Mobile User-agent: AdsBot-Google Disallow: /_api/* Disallow: /_partials* Disallow: /pro-gallery-webapp/v1/galleries/* # Block PetalBot User-agent: PetalBot Disallow: / Sitemap: https://www.courpharmapeanuttrial.com/sitemap.xml

Meta Tags

Title	HOME \|
Description	COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat HOME For more information: Info@courpharma.com 888-551-2687 www.courpharma.com COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Tr
Keywords	N/A

Server Information

WebSite	courpharmapeanuttrial.com
Host IP	23.236.62.147
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

courpharmapeanuttrial.com Valuation

US$764

Last updated: 2022-12-10 01:00:18

courpharmapeanuttrial.com has Semrush global rank of 0. courpharmapeanuttrial.com has an estimated worth of US$ 764, based on its estimated Ads revenue. courpharmapeanuttrial.com receives approximately 88 unique visitors each day. Its web server is located in United States, with IP address 23.236.62.147. According to SiteAdvisor, courpharmapeanuttrial.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$764
Daily Ads Revenue	US$0
Monthly Ads Revenue	US$21
Yearly Ads Revenue	US$254
Daily Unique Visitors	5
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
courpharmapeanuttrial.com. 3599	A	courpharmapeanuttrial.com. 3599	IP: 23.236.62.147
courpharmapeanuttrial.com. 21600 IN	NS		NS Record: ns4.wixdns.net.
courpharmapeanuttrial.com. 21600 IN	NS		NS Record: ns5.wixdns.net.

HtmlToTextCheckTime:2022-12-10 01:00:18

HOME For more information: Info@courpharma.com 888-551-2687 www.courpharma.com COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy CNP-201 is a nanoparticle containing peanut protein that aims to eliminate allergic responses Chicago, Ill. (January 8th, 2022) – COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company’s first-in-human proof-of-concept (Phase 1b/2a) of its lead candidate, CNP-201, for the treatment of peanut allergy. The trial will evaluate the safety and efficacy of CNP-201 in people ages 16 to 55 with peanut allergy and is led by Kari Nadeau, M.D., Ph.D., Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. “Dosing of our first patients with CNP-201 is an important milestone for COUR Pharmaceuticals, as it brings us one step

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Thu, 28 Jul 2022 08:31:35 GMT
Content-Length: 0
Connection: keep-alive
location: https://www.courpharmapeanuttrial.com/
strict-transport-security: max-age=3600
x-wix-request-id: 1658997095.2385604889194326147
Age: 0
Server-Timing: cache;desc=miss, varnish;desc=miss, dc;desc=uw2-pub-1
X-Seen-By: jeslxIFvDH4ulYwNNi+3MiWfEJXUOf1J0Ah0dFlolkk=,GXNXSWFXisshliUcwO20Naon851uhK6HRsxREnrEO9Yh64OM5BSFLe2R9H2I4MupWIHlCalF7YnfvOr2cMPpyw==,m0j2EEknGIVUW/liY8BLLniEmx2jdHh/ZlXwZ6LpuGEG/hKs8AeY1T4OIbgnD+yx,2d58ifebGbosy5xc+FRallR3oEUx2DX0EQfIjIpCyKTLsaIA5W7t8ibvQep3iKdU4C3b39x3uWMStyEMiDmYaw==,2UNV7KOq4oGjA5+PKsX47BChUuzMvEKHAre8Xn85A0QR2rxCTgaJ7/K2Kx9jhAfC,R8nVwPJv9QJL1m78OROO+IzdrL514xvmIf1BJHRThe0=,g1tEHL6KXqacD6ojcO5kMtjyd9l43hTlPniedZH0IESIuY4EIlf0/A+rQUU1+Hlz,adCcrjWN+9jYhIHsscsS5mvxMcOYMt6bE+idnFY4J6kSO5XmrrCSQNDehIjmfew3j4n+NSn3uaaWgwhh/7Gh5w==
Cache-Control: no-cache
X-Content-Type-Options: nosniff

HTTP/2 200 
date: Thu, 28 Jul 2022 08:31:35 GMT
content-type: text/html; charset=UTF-8
link: ; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,
x-wix-request-id: 1658997095.719740415121524876
content-language: en
strict-transport-security: max-age=3600
age: 0
x-seen-by: GXNXSWFXisshliUcwO20NXdyD4zpCpFzpCPkLds0yMcMiRbugkekm+xhVRf/X4Dm,qquldgcFrj2n046g4RNSVFU+wIjSmTlxqMUV00MvxJE=,2d58ifebGbosy5xc+FRalq5TRdwWZNpBQZMn5sRVmq67qiwk/NsszZ0Vbm2yCpbT3QpI/ucnHvfrUjeESIoVeqrS3rObRgKhS5u6U2ywavE=,2UNV7KOq4oGjA5+PKsX47HCc7DfwHPKx9/67HjQqEMOa46R9xNIlpQ4eUPYpBuqs,7npGRUZHWOtWoP0Si3wDp4iHzyATQZvwBB4z2qzqSXE=,ywkbhDzHLtjhjmon1ohv9zDF583DIPtmgDMoc10QJka8I+gQxH14aWuiMQDKc4hBvGQ2Otd3B2C27oTTIAKJtQ==,xTu8fpDe3EKPsMR1jrheEIcvUSYW/bIDxTdfrQGN6EY=,xTu8fpDe3EKPsMR1jrheEIBRo3ZhUtNrH9PB+h7LVcc=,LoUK8/saGAmOxZWtpubo2vNo5ZR3VEYND/u1n/2j95McUBvecGKMozCWCR1NmE2w1hmlUsxFRh9cF83bge1cGzjgv36d5yd1FJxa7kjkGKM=,xTu8fpDe3EKPsMR1jrheEIBRo3ZhUtNrH9PB+h7LVcc=,xTu8fpDe3EKPsMR1jrheEIOaoD167w4+RZ5+Tadfwm0=,/a5ccLSK1HEmwPNg/x6OuuGMcsCHyfO2PiVnsWwkps6DPViXZXS94SuaRbC3niAklOOKK4ukcfye7QsHqf4Osw==
cache-control: no-cache
vary: Accept-Encoding
accept-ranges: bytes
set-cookie: ssr-caching=cache#desc=miss#varnish=miss#dc#desc=eun1_g; Max-Age=20; Expires=Thu, 28 Jul 2022 08:31:55 GMT
server-timing: cache;desc=miss, varnish;desc=miss, dc;desc=eun1_g
x-content-type-options: nosniff
server: Pepyaka/1.19.10
via: 1.1 google
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000,h3-Q050=":443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000,quic=":443"; ma=2592000; v="46,43"

courpharmapeanuttrial.com Whois Information

Domain Name: COURPHARMAPEANUTTRIAL.COM
Registry Domain ID: 2666806282_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.wix.com
Registrar URL: http://www.wix.com
Updated Date: 2022-01-25T19:07:23Z
Creation Date: 2022-01-08T15:36:12Z
Registry Expiry Date: 2023-01-08T15:36:12Z
Registrar: Wix.com Ltd.
Registrar IANA ID: 3817
Registrar Abuse Contact Email: domain-abuse@wix.com
Registrar Abuse Contact Phone: +14154291173
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS4.WIXDNS.NET
Name Server: NS5.WIXDNS.NET
DNSSEC: unsigned
>>> Last update of whois database: 2022-07-28T08:27:20Z <<<

courpharmapeanuttrial.com valuation and analysis